1.
Chan EK, Damoiseaux J, Carballo OG, Conrad K, Cruvinel WM, Francescantonio PL, et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Frontiers Immunol 2015;6:1–13.Web of ScienceGoogle Scholar
2.
Andrade LE, Klotz W, Herold M, Conrad K, Rönnelid J, Fritzler MJ, et al. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med 2018;10:1783–8.Web of ScienceGoogle Scholar
3.
Herold M, Klotz W, Andrade LE, Conrad K, Cruvinel WM, Damoiseaux J, et al. International Consensus on Antinuclear Antibody Patterns: defining negative results and reporting unidentified patterns. Clin Chem Lab Med 2018;10:1799–802.Web of ScienceGoogle Scholar
4.
Chan EK, Damoiseaux J, de Melo Cruvinel W, Carballo OG, Conrad K, Francescantonio PL, et al. Report on the second International Consensus on dense fine speckled Pattern (ICAP) workshop in Dresden 2015. Lupus 2016;25:797–804.CrossrefGoogle Scholar
5.
Damoiseaux J, Andrade LE, Carballo OG, Conrad K, Francescantonio PL, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 2019; pii: annrheumdis-2018-214436. doi: 10.1136/annrheumdis-2018-214436.Web of ScienceGoogle Scholar
6.
Cozzani E, Drosera M, Gasparini G, Parodi A. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014;2014:321359.PubMedGoogle Scholar
7.
Dellavance A, Gallindo C, Soares MG, Silva NP, Mortara RA, Andrade LE. Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific immunofluorescence pattern. Rheumatology (Oxford) 2009;48:632–8.CrossrefPubMedGoogle Scholar
8.
Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514–22.PubMedGoogle Scholar
9.
Shero JH, Bordwell B, Rothfield NF, Earnshaw WC. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986;231:737–40.PubMedCrossrefGoogle Scholar
10.
Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 2005;32:2144–9.PubMedGoogle Scholar
11.
Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. ANA HEp-2 pattern is a critical parameter for discriminating ANA-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191–200.CrossrefPubMedGoogle Scholar
12.
Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol 1994;3:587–92.Google Scholar
13.
Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000;105:1211–20.PubMedCrossrefGoogle Scholar
14.
Ochs RL, Mahler M, Basu A, Rios-Colon L, Sanchez TW, Andrade LE, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med 2016;16:27393.Web of ScienceGoogle Scholar
15.
Yamada K, Senju S, Shinohara T, Nakatsura T, Murata Y, Ishihara M, et al. Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett 2001;78:161–8.PubMedCrossrefGoogle Scholar
16.
Ayaki M, Ohoguro N, Azuma N, Majima Y, Yata K, Ibaraki N, et al. Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity 2002;35:319–27.PubMedCrossrefGoogle Scholar
17.
Okamoto M, Ogawa Y, Watanabe A, Sugiura K, Shimomura Y, Aoki N, et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun 2004;23:257–66.PubMedCrossrefGoogle Scholar
18.
Watanabe K, Muro Y, Sugiura K, Tomita Y. IgE and IgG (4) autoantibodies against DFS70/LEDGF in atopic dermatitis. Autoimmunity 2011;44:511–9.Web of ScienceCrossrefPubMedGoogle Scholar
19.
Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892–900.PubMedCrossrefGoogle Scholar
20.
Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104–10.CrossrefWeb of SciencePubMedGoogle Scholar
21.
Mahler M, Hanly JG, Fritzler MJ. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 2011;11:642–45.Web of ScienceGoogle Scholar
22.
Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424–32.CrossrefGoogle Scholar
23.
Damoiseaux JG, Tervaert JW. From ANA to ENA: how to proceed? Autoimmun Rev 2006;5:10–7.CrossrefPubMedGoogle Scholar
24.
Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011;4:194–200.Web of ScienceGoogle Scholar
25.
Bentow C, Fritzler MJ, Mummert E, Mahler M. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Autoimmun Highlights 2016;7:8.CrossrefWeb of ScienceGoogle Scholar
26.
Sheldon J, Dellavance A. Strategies for building reference standards for autoantibodies. Front Immunol 2015;6:194.Web of SciencePubMedGoogle Scholar
27.
Chan EK, Fritzler MJ, Wiik A, Andrade LE, Reeves WH, Tincani A, et al. Autoantibody Standardization Committee in 2006. Autoimmun Rev 2007;6:577–80.PubMedWeb of ScienceCrossrefGoogle Scholar
28.
Jacobs JF, Bossuyt X. Standardization and harmonization of autoimmune diagnostics. Clin Chem Lab Med 2018;56:1563–7.Web of ScienceCrossrefPubMedGoogle Scholar
29.
Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, et al. Anti-DFS70 antibodies detected by immunoblot methods: a reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods 2016;436:50–3.Web of ScienceCrossrefPubMedGoogle Scholar
30.
Bonroy C, Schouwers S, Berth M, Stubbe M, Piette Y, Hoffman I, et al. The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clin Chem Lab Med 2018;56:1090–9.PubMedWeb of ScienceCrossrefGoogle Scholar
31.
Shovman O, Gilburd B, Chayat C, Amital H, Langevitz P, WatadA, et al. Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol 2017;36:121–6.PubMedGoogle Scholar
32.
Shoenfeld Y, Cervera R, Haass M, Kallenberg C, KhamashtaM, Meroni P, et al. EASI – the European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. Ann N Y Acad Sci 2007;1109:138–44.CrossrefWeb of ScienceGoogle Scholar
33.
Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as antinuclear antibodies. Ann Rheum Dis 2014;73:17–23.PubMedCrossrefGoogle Scholar
34.
Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I, Borghi MO. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol 2014;10:35–43.CrossrefPubMedWeb of ScienceGoogle Scholar
35.
Seeling M, Bruckner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? Nat Rev Rheumatol 2017;13:621–30.PubMedWeb of ScienceCrossrefGoogle Scholar
36.
Merlini G, Blirup-Jensen S, Johnson AM, Sheldon J, Zegers I. IFCC Committee on Plasma Proteins (C-PP). Standardizing plasma protein measurements worldwide: a challenging enterprise. Clin Chem Lab Med 2010;48:1567–75.PubMedGoogle Scholar
37.
Infantino M, Shovman O, Pérez D, Grossi V, Manfredi M, Benucci M, et al. A better definition of the anti-DFS70 antibody screening by IIF methods. J Immunol Methods 2018;461:110–6.Web of SciencePubMedCrossrefGoogle Scholar
38.
Pena SD, Bastos-Rodrigues L, Pimenta JR, Bydlowski SP. DNA tests probe the genomic ancestry of Brazilians. Braz J Med Biol Res 2009;42:870–6.PubMedCrossrefGoogle Scholar
39.
Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003;100:177–82.CrossrefGoogle Scholar
Comments (0)